MONTREAL, Q.C. (June 28, 2022) – On May 31, 2022, Medisca, a global supplier of pharmaceutical compounding products, acquired DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.

“During this time of flux and uncertainty, our goal is to preserve and protect a product line that has had such a positive impact in shaping the compounding industry,” said Panagiota Danopoulos, Senior Vice President, Global Strategy & Innovation at Medisca.

Launched in 1997, DIFFUSIMAX® is a pioneer brand that has paved the way for PLO gels. Developed by a physician for physicians, DIFFUSIMAX® and DIFFUSIMAX®10 are the go-to topical vehicles for many providers across Canada. In use for 25 years and backed by dozens of stability studies for extended beyond-use dating, DIFFUSIMAX® is scientifically tried and tested with well-established brand equity.

“Striking this partnership with Medisca will create new possibilities for DIFFUSIMAX® by tapping into the inherent commercialization strengths of Medisca, while creating an opportunity for us to dedicate full efforts toward our passion in R&D, manufacturing, and consultative work,” said Dr. Kerry Siminoski, President of Maxima Pharmaceuticals.

DIFFUSIMAX® and DIFFUSIMAX®10 will continue to be manufactured in Edmonton, Alberta under the current Maxima leadership team and will be offered in both Pre-Mixed Cream and Compounding Kit formats.  The brand will be available exclusively through major Canadian wholesalers. Medisca is also committed to developing additional resources to support providers, including access to formulas, stability study reports and more.

As a complement to the existing Medisca MediFlo™ PLO product line, the addition of DIFFUSIMAX® and DIFFUSIMAX®10 create a robust PLO gel portfolio designed to meet the diverse needs of compounding pharmacies across Canada.

For questions on these products, please contact the Medisca Compounding Services team at compoundingservices@medisca.com or at 1-800-665-6334 ext. 1203.

About MEDISCA

Medisca is a global corporation with locations throughout North America, Australia, and Europe, that contributes to healthcare by leveraging strong partnerships that deliver customized solutions with an unwavering commitment to quality and innovation. Backed by 30+ years and a strong foundation in pharmaceutical compounding supply, Medisca is a business-to-business company that delivers comprehensive offerings by providing value, consistency, responsiveness, and loyalty. As Partners in Wellness, Medisca offers an unfailing devotion to improving lives across a multitude of needs and people. For more information visit www.medisca.com and follow us on LinkedIn, Facebook, Twitter, and YouTube.

Contact:

Adam Pinsky